Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBX5 antisense RNA 1 (TBX5-AS1)
- Target
- TBX5-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Enhancer RNA (eRNA), Antisense RNA
01
Overview
TBX5 antisense RNA 1 (TBX5-AS1) is a long non-coding RNA classified as both an antisense RNA and an enhancer RNA, transcribed from the TBX5 genomic locus. It is non-protein coding and modulates expression of the TBX5 gene, which encodes a T-box transcription factor critical for heart development and tumor suppression. TBX5-AS1 is mainly nuclear and can form RNA–RNA duplexes with the sense TBX5 transcript, thereby affecting TBX5 mRNA stability and expression. Its downregulation has been implicated in various cancers and congenital heart diseases: in cancer, TBX5-AS1 acts as a tumor suppressor by inactivating the PI3K/AKT pathway, thereby inhibiting cell proliferation, migration, and invasion, and promoting apoptosis. In Tetralogy of Fallot—a congenital heart defect—hypermethylation of TBX5-AS1 leads to decreased TBX5 expression and impaired proliferation. TBX5-AS1 is under investigation as a diagnostic and prognostic biomarker and potentially as a therapeutic target, though no drugs directly target it yet and mechanistic details remain to be clarified.
- Other names
- TBX5 antisense RNA 1 (non-protein coding)TBX5-AS1lncRNA TBX5-AS1TBX5-AS1:2
02
Mechanism of action
Inactivation of PI3K/AKT pathway, resulting in suppressed cancer cell phenotype (proliferation, migration, invasion) and increased apoptosis
03
Biological functions
Regulation of gene expressionChromatin looping and stability (via enhancer activity)Regulation of cell proliferationApoptosis induction in cancer cellsCell migration and invasion regulation
04
Disease associations
Cancer (including non-small cell lung cancer, adrenocortical carcinoma, uterine corpus endometrial carcinoma, lung squamous cell carcinoma, breast cancer, gastric cancer, colon cancer, esophageal carcinoma)Cardiovascular disease (specifically congenital heart disease, Tetralogy of Fallot)
05
Safety considerations
None directly reported. Therapeutic challenges include limited knowledge of lncRNA targeting, off-target effects, and delivery methods for non-coding RNA therapeutics
06
Interacting drugs
None directly reported; PI3K pathway activators (e.g., 740Y-P, used experimentally to probe mechanism)
07
Biomarkers
TBX5-AS1 expression (potential diagnostic/prognostic biomarker for lung adenocarcinoma and NSCLC)Potential marker for Tetralogy of Fallot and other congenital heart diseases
Beyond the preview
Go deeper on TBX5 antisense RNA 1 (TBX5-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBX5 antisense RNA 1 (TBX5-AS1).